Exozymes Inc.'s Capital Markets Advisor, Sanjeev Srivastava, spoke at the Beryl Elites' Investment Conference in New York City, highlighting a pivotal shift in biomanufacturing. Srivastava compared the industry’s advancements to a “ChatGPT moment,” emphasizing eXoZymes’ breakthrough technology that enables enzymes to function outside of cells. He explained that this innovation allows for the cost-effective and unprecedented production of medicines, nutraceuticals, and chemicals that were previously unattainable through natural processes, marking an exciting development for the sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.